Memo Therapeutics AG is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The company’s lead program is potravitug, targeting BKPyV infection in kidney transplant recipients. Its core assets are supported by its proprietary DROPZYLLA antibody repertoire copying engine with high-throughput screening capabilities.
Investment Rounds
Capital activity and funding progression
| Amount | Valuation | Date | Round | |
|---|---|---|---|---|
| €200 M | — | Jul, 2026 | acquisition | View |
Industries
Frequently Asked Questions
Where is Memo Therapeutics AG located?
Memo Therapeutics AG is located in Schlieren / Zurich, Switzerland.
What industries does Memo Therapeutics AG operate in?
Memo Therapeutics AG operates in the following industries: biotechnology, therapeutics, antibodies, rare disease.
How much total funding has Memo Therapeutics AG raised?
Memo Therapeutics AG has raised a total of $200,000,000.
Who are the investors in Memo Therapeutics AG?
The investors in Memo Therapeutics AG are: Ipsen.
What is the primary business focus of Memo Therapeutics AG?
Memo Therapeutics AG is a late-stage biotechnology company that translates unique human immune responses into best-in-class therapeutic antibodies to treat patients suffering from viral infections and cancer.
What is the lead clinical program of Memo Therapeutics AG?
The company's lead program is potravitug, a first-in-class, highly potent human monoclonal antibody designed to treat BK polyomavirus infection in kidney transplant recipients.
What technology platform does Memo Therapeutics AG utilize for drug discovery?
Memo Therapeutics AG employs a proprietary technology platform called DROPZYLLA, which is an antibody repertoire copying engine that enables high-throughput screening and discovery of superior therapeutic antibodies.
What is the status of Memo Therapeutics AG following the agreement with Ipsen?
In July 2026, Ipsen entered into a definitive agreement to acquire all issued and outstanding shares of Memo Therapeutics AG, with a deal value exceeding 700 million EUR. As part of this transaction, assets and employees not related to the potravitug program will be transferred to a newly incorporated company, Memorises Bio, which will remain with the original shareholders of Memo Therapeutics AG.